Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Price, News & Analysis

G1 Therapeutics logo

About G1 Therapeutics Stock (NASDAQ:GTHX)

Advanced Chart

Key Stats

Today's Range
$7.15
$7.15
50-Day Range
$7.08
$7.15
52-Week Range
$1.08
$7.19
Volume
N/A
Average Volume
1.70 million shs
Market Capitalization
$373.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Stock News Headlines

Drug developer seeks $100M for new cancer treatment
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
G1 Therapeutics Inc.
Hold Rating Affirmed Amid G1 Therapeutics’ Acquisition by Pharmacosmos
See More Headlines

GTHX Stock Analysis - Frequently Asked Questions

G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative net margin of 76.93% and a negative trailing twelve-month return on equity of 136.98%.
Read the conference call transcript
.

G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that G1 Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX), Pfizer (PFE), NVIDIA (NVDA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/01/2024
Today
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GTHX
CIK
1560241
Employees
170
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.97 million
Net Margins
-76.93%
Pretax Margin
-73.83%
Return on Equity
-136.98%
Return on Assets
-39.33%

Debt

Debt-to-Equity Ratio
1.34
Current Ratio
2.48
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$58.20 million
Price / Sales
6.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.68 per share
Price / Book
10.51

Miscellaneous

Outstanding Shares
52,281,000
Free Float
49,087,000
Market Cap
$373.81 million
Optionable
Optionable
Beta
1.66

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:GTHX) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners